Seeking Alpha

stockpucker's  Instablog

  • on Fund Holdings
Send Message
Affinity for activist campaigns and targeted stocks.
My company:
My blog:
  • The Winner Of The Pharma Battle Royale 0 comments
    Apr 18, 2013 9:16 PM | about stocks: CVS, WBA

    Be sure to check out our detailed stock analysis (click here). CVS Caremark (NYSE: CVS) and Walgreen (NYSE: WAG) are the two leaders in the pharma industry, however, the questions is, which is the better investment? A quick look at the valuation and the continued success of CVS' market share gains could mean that CVS is your best bet in the pharma industry.

    Top pick

    CVS is the largest provider of prescription and related health care services in the U.S. The company has three segments, pharmacy services, retail pharmacy, and corporate. Its pharmacy services business provides a full range of prescription benefit management (NYSEMKT:PBM) services, including mail order pharmacy services, specialty, and plan design and administration.

    CVS' retail segment continued its growth last quarter, with revenue increasing 5% on the back of a 4% growth in same-store sales. This was in part triggered by the benefit from market gains due to the Express Scripts-Walgreen contract fallout. As for its other initiative, MinuteClinics, the segment posted impressive growth last quarter, up 38% year over year and adding 31 new clinics during the quarter.


    Stocks: CVS, WBA
Back To stockpucker's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.